olivLaw · US equity research
Viemed Healthcare, Inc. VMD
Services-Misc Health & Allied Services, NEC · SIC 8090 · Vertical: Services-Misc Health & Allied Services, NEC (SIC 8090)
Viemed Healthcare provides home medical equipment and post-acute services, focused on respiratory, chronic care and women's health across all 50 US states. Revenue in the second quarter of 2026 reached a company record of 78.1 million USD, and the company has updated its 2026 guidance.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Viemed Healthcare, Inc. (VMD) stock was 9.01 USD (−10.88% on the day), with market capitalisation 341.4 m USD, P/E 23.7 on diluted EPS of 0.38 USD over the last 12 months, beta 0.45, 52-week range 6.26–12.33 USD. Latest reported quarter (Q3 2026): revenue of 80.7 m USD (+12.2% YoY), net income of 4.6 m USD (+32.0% YoY), diluted EPS 0.11 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 41.0
- weak (30–45)
- Bollinger (20, 2)
- 9.21 – 10.15
- below the lower band · %B -0.21 · band width 9.7%
- SMA 50 / 200
- 9.26 / 9.60
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- 0.06 / 0.12
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −3.4% | −1.1% | −2.3 pp | — |
| 3 months | −5.4% | −0.5% | −4.9 pp | — |
| 6 months | −2.2% | +4.4% | −6.6 pp | — |
| Year to date | +21.3% | +12.3% | +8.9 pp | — |
| 1 year | +40.1% | +13.5% | +26.6 pp | +15.1% |
| 3 years | +28.2% | +76.4% | −48.2 pp | −7.5% |
| 5 years | +48.2% | +63.7% | −15.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 60.7 m | 59.1 m | 63.1 m | 71.9 m | 76.2 m | 75.4 m | 78.1 m | 80.7 m |
| Cost of revenue | 24.6 m | 25.9 m | 26.3 m | 30.6 m | 32.1 m | 32.6 m | 33.0 m | 34.5 m |
| Gross profit | 36.1 m | 33.3 m | 36.7 m | 41.3 m | 44.1 m | 42.8 m | 45.0 m | 46.2 m |
| Research & development | 803.0 k | 797.0 k | 847.0 k | 775.0 k | 598.0 k | 579.0 k | 504.0 k | 501.0 k |
| SG&A | 28.2 m | 28.4 m | 28.8 m | 31.9 m | 32.2 m | 34.8 m | 37.1 m | 35.5 m |
| Operating income | 6.5 m | 3.8 m | 5.1 m | 5.6 m | 8.4 m | 4.3 m | 4.5 m | 7.0 m |
| Depreciation & amortisation | 6.4 m | 6.6 m | 353.0 k | 397.0 k | 7.6 m | 7.6 m | 388.0 k | 392.0 k |
| Interest expense | — | 179.0 k | 132.0 k | 507.0 k | — | 305.0 k | 248.0 k | 177.0 k |
| Pre-tax income | 6.3 m | 3.7 m | 5.0 m | 5.1 m | 8.0 m | 4.0 m | 4.1 m | 6.8 m |
| Income tax | 1.9 m | 952.0 k | 1.7 m | 1.5 m | 2.2 m | 1.3 m | 1.2 m | 2.0 m |
| Net income | 4.3 m | 2.6 m | 3.2 m | 3.5 m | 5.6 m | 2.6 m | 2.8 m | 4.6 m |
| Diluted EPS | 0.10 ≈ | 0.06 | 0.08 | 0.09 | 0.14 ≈ | 0.06 | 0.07 | 0.11 |
| Operating cash flow | 15.0 m | 2.9 m | 12.3 m ≈ | 18.4 m ≈ | 18.4 m | 8.1 m | 15.9 m ≈ | 11.5 m ≈ |
| Capex | 11.8 m | 15.5 m | 8.1 m ≈ | 7.6 m ≈ | 8.7 m | 6.7 m | 8.5 m ≈ | 8.6 m ≈ |
| Share repurchases | 0 | 0 | 1.7 m ≈ | 11.6 m ≈ | 0 | 1.4 m | 5.3 m ≈ | 977.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 38 percentile of its own 29-quarter history (min 9.9, median 26.5, max 63.8; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.5 m | 80.3 m | 131.3 m | 117.1 m | 138.8 m | 183.0 m | 224.3 m | 270.3 m |
| Revenue YoY | unavailable | +24.5% | +63.6% | −10.8% | +18.6% | +31.8% | +22.5% | +20.5% |
| Net income | 9.5 m | 8.5 m | 31.5 m | 9.1 m | 6.2 m | 10.2 m | 11.3 m | 14.9 m |
| Net income YoY | unavailable | −10.3% | +269.9% | −71.1% | −31.8% | +64.6% | +10.0% | +32.6% |
| Diluted EPS | 0.24 | 0.21 | 0.78 | 0.22 | 0.16 | 0.25 | 0.28 | 0.37 |
| Diluted EPS YoY | unavailable | −12.5% | +271.4% | −71.8% | −27.3% | +56.3% | +12.0% | +32.1% |
| net % | 14.7% | 10.6% | 24.0% | 7.8% | 4.5% | 5.6% | 5.0% | 5.5% |
| Free cash flow | 16.3 m | 5.7 m | 22.1 m | 2.8 m | 4.9 m | 19.1 m | 1.3 m | 11.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 13.5 m USD
- Financial debt
- 12.4 m USD
- Net debt
- -1.1 m USD
- Equity
- 143.5 m USD
- Total assets
- 199.2 m USD
- Debt / equity
- 0.09x
- Current ratio
- 1.18x
- ROE
- 10.8%
- ROA
- 7.9%
- FCF margin
- 4.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 131.3 m | 117.1 m | 138.8 m | 183.0 m | 224.3 m | 270.3 m | SEC (XBRL)· 04 Mar 2026verified |
| Cost of revenue | 51.2 m | 43.7 m | 54.2 m | 70.2 m | 91.1 m | 114.8 m | SEC (XBRL)· 04 Mar 2026verified |
| Gross profit | 80.1 m | 73.4 m | 84.7 m | 112.8 m | 133.2 m | 155.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Research & development | 1.1 m | 2.1 m | 2.7 m | 2.8 m | 3.1 m | 3.0 m | SEC (XBRL)· 04 Mar 2026verified |
| SG&A | 52.8 m | 54.9 m | 68.2 m | 87.9 m | 106.2 m | 121.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Operating income | 26.8 m | 11.6 m | 8.3 m | 14.3 m | 17.9 m | 22.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Depreciation & amortisation | — | — | 15.6 m | 21.9 m | 25.4 m | 28.6 m | SEC (XBRL)· 04 Mar 2026verified |
| EBITDA | — | — | 23.9 m ≈ | 36.2 m ≈ | 43.3 m ≈ | 51.6 m ≈ | SEC (XBRL)· 04 Mar 2026derived |
| Pre-tax income | 26.4 m | 12.5 m | 9.0 m | 14.4 m | 16.2 m | 21.8 m | SEC (XBRL)· 04 Mar 2026verified |
| Income tax | -5.2 m | 3.4 m | 2.8 m | 4.1 m | 4.8 m | 6.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Net income | 31.5 m | 9.1 m | 6.2 m | 10.2 m | 11.3 m | 14.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Diluted EPS | 0.78 | 0.22 | 0.16 | 0.25 | 0.28 | 0.37 | SEC (XBRL)· 04 Mar 2026verified |
| Weighted average diluted shares | 40.5 m | 40.7 m | 39.8 m | 40.4 m | 40.8 m | 40.8 m | SEC (XBRL)· 04 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 31.0 m | 28.4 m | 16.9 m | 12.8 m | 17.5 m | 13.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Receivables | 12.4 m | 12.8 m | 15.4 m | 18.5 m | 24.9 m | 25.6 m | SEC (XBRL)· 04 Mar 2026verified |
| Inventories | 2.3 m | 2.5 m | 3.6 m | 4.6 m | 4.3 m | 5.0 m | SEC (XBRL)· 04 Mar 2026verified |
| Current assets | 47.2 m | 47.3 m | 39.7 m | 38.4 m | 52.9 m | 48.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Property, plant & equipment, net | 55.1 m | 62.8 m | 67.7 m | 73.6 m | 76.3 m | 78.8 m | SEC (XBRL)· 04 Mar 2026verified |
| Goodwill | — | — | 0 | 29.8 m | 33.0 m | 58.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Intangibles (excl. goodwill) | — | — | 0 | 567.0 k | 848.0 k | 1.3 m | SEC (XBRL)· 04 Mar 2026verified |
| Total assets | 112.6 m | 118.0 m | 117.0 m | 154.9 m | 177.1 m | 199.2 m | SEC (XBRL)· 04 Mar 2026verified |
| Short-term debt | 1.8 m | 1.5 m | 0 | 1.1 m | 409.0 k | 1.1 m | SEC (XBRL)· 04 Mar 2026verified |
| Long-term debt | 5.8 m | 4.3 m | 0 | 6.0 m | 3.6 m | 11.3 m | SEC (XBRL)· 04 Mar 2026verified |
| Current liabilities | 23.0 m | 17.8 m | 18.9 m | 32.1 m | 37.3 m | 41.1 m | SEC (XBRL)· 04 Mar 2026verified |
| Total liabilities | 30.9 m | 23.1 m | 19.9 m | 41.0 m | 43.8 m | 55.6 m | SEC (XBRL)· 04 Mar 2026verified |
| Equity | 81.7 m † | 94.8 m | 97.1 m | 113.9 m | 133.3 m | 143.5 m | SEC (XBRL)· 04 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 35.1 m | 22.5 m | 27.7 m | 45.2 m | 39.1 m | 51.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Capex | 13.0 m | 19.7 m | 22.9 m | 26.1 m | 37.8 m | 40.0 m | SEC (XBRL)· 04 Mar 2026verified |
| Free cash flow | 22.1 m ≈ | 2.8 m ≈ | 4.9 m ≈ | 19.1 m ≈ | 1.3 m ≈ | 11.9 m ≈ | SEC (XBRL)· 04 Mar 2026derived |
| Investing cash flow | -8.4 m | -19.7 m | -24.0 m | -52.1 m | -30.7 m | -50.2 m | SEC (XBRL)· 04 Mar 2026verified |
| Financing cash flow | -9.1 m | -5.3 m | -15.3 m | 2.8 m | -3.7 m | -5.8 m | SEC (XBRL)· 04 Mar 2026verified |
| Share repurchases | 0 | 0 | 9.6 m | 0 | 0 | 13.2 m | SEC (XBRL)· 04 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 72 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 341.4 m USD
Key indicators
Coverage and freshness
Score by group
- Quality77
- Growth100
- Balance sheet82
- Returns32
- Valuation56
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 3.38 – 9.40 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · not enough peers
- Peers: P/E3.38 – 9.40 (Mid 6.45)6 companies used · median multiple 16.9x · quartiles 8.9x – 24.7xAGL, DVA, FMS, NIVF, PGNY, SHC
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 72/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 11.6% | 74 (on a fixed band) | 12% |
| Net margin · Quality | 5.0% | 60 (vs peers) | 7% |
| FCF conversion · Quality | 136.8% | 100 (on a fixed band) | 7% |
| Revenue CAGR 3Y · Growth | 24.9% | 100 (on a fixed band) | 9% |
| EPS CAGR 3Y · Growth | 32.2% | 100 (on a fixed band) | 9% |
| Net debt / EBITDA · Balance sheet | -0.1x | 100 (on a fixed band) | 12% |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.3x | 38 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 23.7x | 33 (vs peers) | 12% |
| EV/EBITDA · Valuation | 8.4x | 60 (on a fixed band) | 12% |
| FCF yield · Valuation | 6.3% | 78 (on a fixed band) | 9% |
| Shareholder yield (distributions) · Returns | 2.3% | 32 (on a fixed band) | 7% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet82/100 · 2/3 factors with a value
- Growth100/100 · 2/2 factors with a value
- Quality77/100 · 3/3 factors with a value
- Returns· partial32/100 · 1/2 factors with a value
- Valuation56/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Viemed Healthcare, Inc. (VMD). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 270.3 m USD in 2025; YoY growth 20.5%; net margin 5.0%; ROE 11.0%; net debt/EBITDA -0.1x.
The estimated value range is 3.38–9.40 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 6.45 USD, the price of 9.01 USD leaves a potential of -28.4% (value / price − 1) and a margin of safety of -39.8% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 72/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 11.6%
- FCF conversion: 136.8%
- Revenue CAGR 3Y: 24.9%
- EPS CAGR 3Y: 32.2%
- Net debt / EBITDA: -0.1x
- FCF yield: 6.3%
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): Interest coverage, Payout ratio (FCF).
Versus the vertical median
Services-Misc Health & Allied Services, NEC (SIC 8090) · same industry (4-digit SIC) · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| DVADavita Inc. | 12.3 bn | 14.3 | — | 6.5% | +6.5% | +63% / +92% |
| FMSFresenius Medical Care AG | 6.6 bn | 7.0 | 7.0% | 5.0% | +1.5% | −1% / +15% |
| SHCSotera Health Company | 4.5 bn | 26.4 | 27.0% | 14.1% | +5.7% | −9% / +16% |
| PGNYProgyny, Inc. | 2.6 bn | 37.4 | 16.2% | 6.0% | +10.4% | +30% / +0% |
| AGLagilon health, inc. | 1.9 bn | 19.5 | -29.7% | -1.5% | −2.1% | +599% / −57% |
| VMDViemed Healthcare, Inc. | 341.4 m | 23.7 | 11.0% | 5.0% | +20.5% | +40% / +28% |
| CCELCryo-Cell International, Inc. | 39.9 m | — | — | -6.2% | −1.3% | +15% / −7% |
| BRTXBiorestorative Therapies, Inc. | 38.5 m | — | -241.1% | -3,089.6% | −10.3% | +40% / −21% |
| MGRXMangoceuticals, Inc. | 4.1 m | — | -95.1% | -4,791.3% | −26.0% | −83% / −98% |
| NIVFNewgenivf Group Limited | 117.2 k | 0.2 | 77.2% | 209.0% | −13.0% | −100% / −100% |
| MCTACharming Medical Limited | — | — | -0.9% | -0.5% | −22.7% | unavailable / unavailable |
1- and 3-year price returns: for VMD from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 6.37 Total return -29% · Per year -29% | 11.22 Total return 25% · Per year 25% | 16.83 Total return 87% · Per year 87% |
| 3 years | 7.56 Total return -16% · Per year -6% | 14.84 Total return 65% · Per year 18% | 24.23 Total return 169% · Per year 39% |
| 5 years | 8.97 Total return -0% · Per year -0% | 19.62 Total return 118% · Per year 17% | 34.89 Total return 287% · Per year 31% |
- Exit P/E± 3.71
- Net margin± 2.60
- Annual revenue growth± 1.94
- Annual dilution± 0.22
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 03 Aug 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
In brief
Viemed Healthcare provides home medical equipment and post-acute services, focused on respiratory, chronic care and women's health across all 50 US states. Revenue in the second quarter of 2026 reached a company record of 78.1 million USD, and the company has updated its 2026 guidance.
SWOT
Strengths
- The company holds a strong position in home respiratory care, with a record number of ventilator patients and rapid growth in PAP therapy 23. Operating cash generation is solid, and the company is repaying debt and repurchasing shares 3.
- The home clinical care model, supported by licensed respiratory therapists, differentiates it from providers without their own staff 1. Medicare accreditation and state licences create entry barriers for new competitors 1.
- Revenue growth exceeded 20% in 2025 and continued into 2026, showing an ability to grow without depending on a single product line 13.
Weaknesses
- Revenue depends heavily on ventilator rental, a segment whose share has fallen but remains dominant 12. Reliance on a small number of payors, especially Medicare, exposes the company to policy changes 1.
- Adjusted EBITDA guidance for 2026 was lowered, showing that margins are sensitive to costs and investment structure 3. The company depends on external suppliers for equipment and has limited control over pricing 1.
- All operations run through US subsidiaries, so the ability to pay dividends or send funds to the parent company depends on those subsidiaries' cash flows 1.
Opportunities
- Rising demand for PAP therapy and sleep resupply could support expansion into new territories without large location costs 13. A growing share of less capital-intensive services could improve return on investment 3.
- If the home care trend holds, the company could extend its services to new categories of chronic patients 1. Staffing services for third-party institutions could open an additional revenue stream 1.
- Market consolidation could allow acquisitions of smaller providers, provided accreditation and Medicare enrolment do not slow integration 1.
Threats
- Lower reimbursement rates or narrower Medicare coverage could directly hit revenue and profitability 1. Including respiratory categories in competitive bidding could put pressure on prices 1.
- Larger competitors with more resources could erode margins through aggressive pricing or new products 1. Tariffs and equipment shortages could raise supply costs 1.
- Breaches of fraud and abuse rules, or loss of accreditation, could lead to penalties, exclusion from government programmes and reputational damage 1.
Risks
- Dependence on Medicare and reimbursementhigh
A substantial part of revenue comes from Medicare and other third-party payors, and policy changes could reduce revenue quickly 1.
- New ventilator coverage determinationhigh
The medical necessity criteria in the 2025 CMS decision could limit the number of patients eligible for home ventilation 1.
- Concentration on ventilatorsmedium
Ventilator rental remains the largest segment, so any demand or regulatory problem in this area affects a large part of revenue 12.
- Supply chain and tariffsmedium
The company depends on a few equipment suppliers, and tariffs or shortages could raise costs and reduce product availability 1.
- Compliance and accreditation requirementslow
DMEPOS accreditation and Medicare enrolment carry strict standards, and the new rules from 2027 could add administrative pressure 1.
Investment thesis
What would need to be true (bull case)
- If the home care trend and PAP patient growth continue, the company could sustain revenue growth above the sector average 13.
- Operating cash generation and the capacity to repurchase shares point to a solid financial base that could support investment in technology and staff 3.
- Diversification into sleep resupply and women's health could reduce dependence on ventilators over time 23.
What would break the thesis
- If reimbursement cuts or new Medicare criteria spread, margins could fall faster than volumes grow 1.
- The lower 2026 Adjusted EBITDA guidance shows that not all revenue growth is turning into profit 3.
- Competition from larger groups and vertically integrated providers could limit market share and pricing power 1.
What to watch
- Trajectory of revenue and Adjusted EBITDA guidanceQ3 2026
- Ventilator and PAP patient countsQ3 2026
- Effect of the CMS ventilation decision on reimbursement2027
- Medicare accreditation renewal timing and new inspection rules2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 03 Aug 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
The business
Viemed Healthcare, Inc. is a provider of home medical equipment (HME) and post-acute healthcare services in the United States, focused on respiratory, chronic care and women's health products 1. Its model relies on in-home clinical care supported by licensed respiratory therapists, which is designed to lower total costs and hospital readmissions 1. The company trades on Nasdaq under the symbol VMD and its principal executive office is in Lafayette, Louisiana 13.
Revenue comes largely from renting invasive and non-invasive ventilators, which represented 46.6% of revenue in the second quarter of 2026 2. The rest comes from oxygen therapy, sleep apnea management, PAP therapy, sleep resupply, women's health products and staffing services for third-party institutions 12. The company also holds Medicare accreditation and state licences, which makes access to this market heavily regulated 1.
For 2026 Viemed raised the low end and narrowed its full-year revenue guidance, but lowered its Adjusted EBITDA guidance 3. The company said less capital-intensive product and service revenue is growing in share, which could support more predictable performance if the trend holds 3.
Segments
Ventilators and respiratory care
Ventilator rental, including for chronic obstructive pulmonary disease, is the largest revenue source and had a record 12,635 active patients at June 30, 2026 13. Its share of revenue fell from 50.6% in 2025 to 46.6% in the second quarter of 2026 as other services grow 12.
PAP therapy and sleep apnea
PAP therapy and sleep resupply grew strongly in 2026, with more than 37,000 patients by mid-year, following in-home sleep apnea testing 3. This is the fastest-growing reported area, which makes it central to the company's future trajectory 3.
Women's health and staffing
Women's health products such as breast pumps, and recruitment services for external healthcare institutions, complement the portfolio 1. The company employs 417 licensed respiratory therapists, about 29% of staff, which supports both its own services and its staffing offer 2.
Market context
The home medical equipment market is expanding, with projected growth of about 6% a year for respiratory devices and 8% for sleep apnea devices 1. US home healthcare spending could reach 250 billion USD by 2031, growing about 7% a year 1.
The market is consolidating, and larger, financially stable players may benefit from scale while smaller regional providers exit 1. Payor price pressure and value-based contracting could nonetheless limit margins for all providers 1.
Trends
- Shift of care from hospitals to the hometailwind
Moving care from hospitals into the home aligns with Viemed's model and could create new growth opportunities 1. Payors increasingly adopt value-based care models that favour home service providers 1.
- New Medicare coverage for ventilatorsmixed
CMS finalized in June 2025 a national coverage determination for non-invasive ventilation in the home, with clear medical necessity criteria 1. This change could affect patient access, reimbursement and ventilator utilisation, and its effect on revenue remains to be seen 1.
- Reimbursement pressure and competitive bidding reformheadwind
Healthcare cost containment is intensifying, and lower reimbursement rates could reduce profitability 1. CMS reform of the competitive bidding programme could bring respiratory categories into future rounds, which would change pricing conditions 1.
- OBBBA legislation and cost inflationheadwind
The 2025 OBBBA law changes Medicaid and programme funding, with effects mainly from 2027 and 2028, while supply chain costs and tariffs could raise equipment prices 1. The company said tariffs have not yet had a material adverse effect, but uncertainty remains 1.
Competitive position
The respiratory care market is competitive, and larger rivals with greater financial and research resources could reduce Viemed's margins and market share 1. Some competitors are subsidiaries of groups that are vertically integrated into manufacturing, which can give them cost advantages 1.
Consolidation favours companies with enough capital for investment and scale, and small suppliers face pressure to merge or exit 1. Viemed positions itself through a home care model with its own clinical staff, which may differentiate it from smaller rivals 1.
- Regional home medical equipment suppliers
Smaller providers competing for the same respiratory and sleep apnea services, but with limited capital and scale, which leaves them exposed to consolidation 1.
- Subsidiaries or divisions of larger groups
Units of bigger companies with easier access to financing and product development, which can attract patients with competitive offers 1.
- Vertically integrated equipment providers
Companies that combine equipment manufacturing with services, which may allow better prices and lead times than a provider dependent on third parties 1.
- Sleep and home monitoring technology providers
Equivalent or superior products developed by competitors could reduce demand for Viemed's services over time 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity ExpandsYahoo Finance — News · 29 Aug 2026 · EN
The latest news item in our archive is from 29 Aug 2026; the newest SEC filing is from 04 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report04 Nov 2026
- Current report04 Nov 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report20 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report03 Aug 2026
- Current report03 Aug 2026Results of operations · Financial statements and exhibits
- Current report04 Jun 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Current report02 Jun 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report05 May 2026
- Current report05 May 2026Results of operations · Financial statements and exhibits
- Proxy statement22 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Viemed Healthcare, Inc. · 04 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Viemed Healthcare, Inc. · 03 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Viemed Healthcare, Inc. · 03 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.